1427 ET - WELL Health Technologies is set to continue its acquisitive momentum in 2025, and TD Cowen's David Kwan thinks WELL's unannounced additions could be positive for the balance sheet. In a report, the analyst says that these could account for almost C$75 million in revenue and C$8-C$9 million in Ebitda, which would represent about 6% upside to TD's current forecasts. Kwan says WELL's current M&A pipeline includes 12 letters-of-intent reflecting C$65 million in revenue and in-line Ebitda margins. "With a continued robust M&A pipeline, we believe WELL will remain active with its M&A program that should help it drive strong, profitable growth," Kwan says. Shares are up 1.2% to C$6.70. (adriano.marchese@wsj.com)
(END) Dow Jones Newswires
January 14, 2025 14:27 ET (19:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。